Weight loss is superior to exercise in improving the atherogenic lipid profile in a sedentary, overweight population with stable coronary artery disease: A randomized trial

Lene Rørholm Pedersen a,*, Rasmus Huan Olsen a, Christian Anholm b, Rosemary L. Walzem c, Mogens Fenger d, Jesper Eugen-Olsen e, Steen Bendix Haugaard b, Eva Prescott a

a Department of Cardiology, Bispebjerg University Hospital, University of Copenhagen, Copenhagen, Denmark
b Department of Internal Medicine, Hvidovre and Amager University Hospitals, University of Copenhagen, Copenhagen, Denmark
c Faculty of Nutrition, Texas A&M University, College Station, TX, USA
d Department of Medical Biochemistry, Genetics and Molecular Biochemistry, Hvidovre Hospital, University of Copenhagen, Copenhagen, Denmark
e Clinical Research Center, Hvidovre Hospital, University of Copenhagen, Copenhagen, Denmark

1. Introduction

Initiation and progression of atherosclerotic plaque are mediated by deposition of atherogenic lipoproteins in the intima and media of the arterial wall eliciting an inflammatory response. Unstable atherosclerotic plaque prone to rupture is characterized by perivascular inflammation and a lipid-rich core. Plaque rupture is believed to be the cause of 60–70% of myocardial infarctions [1,2]. In clinical practice amounts of low and high-density lipoprotein

Abbreviations: AIT, Aerobic interval training; BMI, Body mass index; CAD, Coronary artery disease; CRP, C-reactive protein; HDL, High density lipoprotein; FFM, Fat free mass; IL6, Interleukin 6; LDL, Low density lipoprotein; LED, Low energy diet; TNFα, Tumor necrosis factor alpha; SuPAR, Soluble urokinase plasminogen activator receptor; TRL, Triglyceride-rich lipoprotein; VO2peak, Peak aerobic capacity.

* Corresponding author. Department of Cardiology, Bispebjerg University Hospital, Bispebjerg Bakke 23, DK-2400 Copenhagen, NV, Denmark. E-mail address: lrpopedersen@gmail.com (L.R. Pedersen).

http://dx.doi.org/10.1016/j.atherosclerosis.2016.01.001
0021-9150/© 2016 Elsevier Ireland Ltd. All rights reserved.

Atherosclerosis 246 (2016) 221–228
(LDL and HDL) cholesterol in blood are used to monitor lipid-lowering treatment and assess cardiovascular risk [3]. However, measurement of lipoprotein density and particle size could provide a more accurate risk estimation by taking into account the small, dense atherogenic lipoprotein particles with triglyceride-rich, cholesterol-depleted cores [4–8].

The pro-inflammatory cytokines tumor necrosis factor alpha (TNFα) and interleukin 6 (IL6) are believed to be involved in the pathogenesis of atherosclerosis [2]. A meta-analysis comprising 29 studies associated IL6, TNFα and the inflammatory marker C-reactive protein (CRP) to increased cardiovascular risk independent of traditional risk factors in healthy populations [9]. Increased IL6, CRP and TNFα predicts a poor prognosis in stable and unstable CAD [10–12]. Recently, the inflammatory marker soluble urokinase plasminogen activator receptor (sPAPAR) was linked to atherogenesis, cardiovascular risk in healthy populations and prognosis following ST-elevation myocardial infarction [13–15].

Dyslipidemia and low-grade inflammation are associated with obesity and sedentarism [2,3,16]. The current paper compares the effects of 12 weeks’ aerobic interval training (AIT) to those of a rapid weight loss using a low energy diet (LED) on lipid profile atherogenicity and low-grade inflammation. We recently demonstrated that both interventions elicited similar decreases in total cholesterol, triglycerides and non-HDL-cholesterol and reduced visceral abdominal fat; albeit, LED was superior to AIT [17]. Since low-grade inflammation and lipoprotein particle size [18,19] have been associated with visceral adipose tissue we hypothesize a superior effect of LED in terms of decreasing inflammatory response and lipoprotein atherogenicity.

2. Methods

2.1. Study design

Population, study design and intervention of this randomized trial has been described in detail previously [20]. Main inclusion criteria were CAD diagnosed >6 months prior to inclusion, BMI 28–40 kg/m2, age 45–75 years and no diabetes. Participants were randomized to either 12 weeks’ supervised AIT at 85–90% of VO2peak three times/week or a weight loss program using an LED (800–1000 kcal/day, the Cambridge Weight Plan, Northants, UK) for 8–10 weeks, followed by a 2–4 week weight maintenance diet to ensure a non-catabolic state at follow-up. The AIT group was examined >18 h after the last exercise session [20].

Per protocol adherence to intervention was a priori defined as: ≥5% weight loss in the LED group and training attendance ≥60% overall and ≥50% the last two weeks of the intervention in the AIT group. The aim of the study was a direct comparison of weight loss/flow reserve [20,23]. Categorical data, including IL6 dichotomized at 2 ng/mL, are presented as number (percentage) and compared using χ2 or Fischer’s exact test. McNemar’s test was used for within-group comparison of IL6. Continuous data are presented as mean (SD) or median (Q1, Q3) if not normally distributed. An appropriate t-test was used for comparisons of paired (within-group) and unpaired (between-group) continuous data. Logarithmic transformation (log10) was used.

2.2. Body composition and peak aerobic capacity

As previously published [17] body fat mass and fat free mass (FFM) was determined by dual X-ray absorptiometry. Magnetic resonance imaging (MRI) estimated abdominal visceral and subcutaneous fat. For logistic and medical reasons only 33 participants underwent MRI at both baseline and follow-up. A bicycle ergometer and breath-by-breath gas exchange measurements determined peak aerobic capacity (VO2peak). To account for changes in body composition VO2peak was expressed as mL/kg FFM0.67/min.

2.3. Blood samples: collection and analyses

All blood samples were drawn from an intravenous cannula in an antecubital vein in the morning after a 10-h overnight fast. Samples were centrifuged for 10 min at 3500 rpm (Universal 320R, Hettich Centrifugen, Tuttingen, Germany) and plasma was stored at −80 °C.

2.3.1. Density profiling

Density profiling was carried out using ultracentrifugation [21,22] with a bismuth sodium ethylenediaminetetraacetic acid (NaBiEDTA, TCI America, Portland, OR) gradient solution and lipoproteins pre-stained with the lipophilic fluorescent probe NBD C6 (ceramide (6-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)hexanoyl)sphingosine, Invitrogen, Carlsbad, CA). Each sample was centrifuged in an ultracentrifuge tube (Beckman Coulter Inc., Palo Alto, CA) at 120,000 rpm, for 6 h using an Optima TLX ultracentrifuge and a TLA 120.2 fixed-angle rotor (Beckman–Coulter, Palo Alto, CA). An image of tube was obtained and analyzed using a digital OptronicsMicrofireCamera (599808, Goleta, CA) with a Fiber-Lite MH-100 Illuminator as a light source (MH100A, Edmund Industrial Optics, Barrington, NJ). A digital color microscope camera (599808, Optronics, Goleta, CA) was used to record the image. The image was converted to a density profile using a commercially available software program (OriginPro 7.5, Microcal Software Inc., Northampton, MA) depicting fluorescence emission in pixels at any given point versus tube coordinate (6–33 mm length). For a more detailed description of the method and an example of the density profile curve see online appendix B.

The lipoproteins were divided into subfractions based on density. The amount of each subfraction was determined as the area under the density profile curve which is determined as the total amount of pixels per defined subfraction as indicated by the length along the tube. Lipoprotein density is inversely related to lipoprotein particle size (Table 2) [4]. Average particle size was calculated using the percentage each subfraction constituted of total LDL or HDL.

2.3.2. Inflammatory markers

TNFα was determined using an enzyme-linked immunosorbent assay (ELISA, DRG instruments Marburg, Germany). SupAR was analyzed using suPARnostics® ELISA (ViroGates, Copenhagen, Denmark). CRP was determined using a high sensitivity assay ELISA with a lower detection limit of 0.2 mg/L. The ELISA used for IL6 had a lower detection level of 2 pg/mL. (Immulet 2000, Siemens Healthcare diagnostics, LA, CA). All kits were used according to the manufacturer instructions. The intra-assay variation was 3.2%, 3.3–4.5%, 2.8–8.7% and 3.3–4.9% whereas inter-assay variation was 5.4%, 6.3–6.6%, 3.1–8.7% and 4.6–7.2% for suPAR, TNFα, CRP and IL6, respectively. Baseline and 12-week samples were analyzed using the same assay.

2.4. Statistics

Sample size calculation was published earlier and was based on the primary endpoint of the study, coronary flow reserve [20,23]. Categorical data, including IL6 dichotomized at 2 ng/mL, are presented as number (percentage) and compared using χ2 or Fisher’s exact test. McNemar’s test was used for within-group comparison of IL6. Continuous data are presented as mean (SD) or median (Q1, Q3) if not normally distributed. An appropriate t-test was used for comparisons of paired (within-group) and unpaired (between-group) continuous data. Logarithmic transformation (log10) was used.

Downloaded from ClinicalKey.com at BS - University of Copenhagen June 28, 2016. For personal use only. No other uses without permission. Copyright ©2016. Elsevier Inc. All rights reserved.
performed on TNFα, CRP and suPAR ensuring a normal distribution. Linear regression including the entire population was used to describe the correlation between changes in body fat distribution and triglycerides, and lipoprotein particle size and log transformed inflammatory markers. The significance level was set to $P < 0.05$.

Stata 13.1 software (StataCorp, College Station, TX, USA) was used for all analyses.

### 3. Results

#### 3.1. Population and intervention

Seventy participants were included. Of them 57 (81%) were male, median age 63 (58; 71) years and median BMI 31.3 (29.7; 33.7). After 12 weeks 65 (93%) participants were re-examined; 31 (88.6%) and 34 (97.1%) in the AIT and LED group, respectively, and included in the intention-to-treat analyses whereas 26 (74.2%) and 29 (82.9%) met per protocol criteria in the AIT and LED group, respectively. In the present paper, one AIT participant was excluded from the analyses due to discontinuation of statin treatment prior to follow-up possibly affecting the lipid profile and low-grade inflammation (Fig. 1). The population was largely asymptomatic and contemporarily treated with regard to blood pressure and lipids [17]. Baseline characteristics for participants included in per protocol analyses are presented in Table 1.

#### 3.2. Lipoprotein density profiling

Total lipoprotein decreased significantly in both groups (Table 2). The atherogenic triglyceride-rich lipoproteins (TRL, i.e. chylomicrons, very low and intermediate density lipoprotein) [4] decreased following both interventions, although only significantly after LED. Total LDL decreased significantly in both groups. LED and AIT decreased LDL2, LDL3 and LDL4 amounts similarly whereas a trend for LED to have greater effect on LDL5 was seen. This resulted in a less atherogenic lipoprotein profile following LED with a larger contribution to total LDL from the large, less dense LDL1 and LDL3 and a simultaneous decrease in the contribution of

**Table 1** Baseline characteristics.

<table>
<thead>
<tr>
<th></th>
<th>AIT (n = 26)</th>
<th>LED (n = 29)</th>
<th>$P$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male (%)</td>
<td>22 (85%)</td>
<td>21 (72%)</td>
<td>0.19</td>
</tr>
<tr>
<td>Age (years)</td>
<td>62.3 (5.7)</td>
<td>63.6 (6.8)</td>
<td>0.61</td>
</tr>
<tr>
<td>Body mass index (kg/m²)</td>
<td>31.7 (29.6; 34.8)</td>
<td>31.1 (29.9; 32.7)</td>
<td>0.48</td>
</tr>
<tr>
<td>Visceral fat (cm², n = 14/14)</td>
<td>246 (62)</td>
<td>277 (99)</td>
<td>0.34</td>
</tr>
<tr>
<td>Subcutaneous fat (cm², n = 14/14)</td>
<td>256 (70)</td>
<td>244 (81)</td>
<td>0.80</td>
</tr>
<tr>
<td>Body fat mass (kg)</td>
<td>33.3 (8.3)</td>
<td>33.3 (7.9)</td>
<td>0.99</td>
</tr>
<tr>
<td>VO₂peak (mL/kg/min)</td>
<td>20.7 (4.9)</td>
<td>20.6 (5.0)</td>
<td>0.83</td>
</tr>
<tr>
<td>VO₂peak (mL/kg FFM⁰⁶⁷/min)</td>
<td>124 (24)</td>
<td>124 (25)</td>
<td>1.00</td>
</tr>
<tr>
<td>Total-cholesterol (mmol/L)</td>
<td>4.3 (0.8)</td>
<td>4.1 (0.7)</td>
<td>0.28</td>
</tr>
<tr>
<td>HDL-cholesterol (mmol/L)</td>
<td>1.2 (0.3)</td>
<td>1.1 (0.2)</td>
<td>0.50</td>
</tr>
<tr>
<td>Non-HDL-cholesterol (mmol/L)</td>
<td>3.1 (0.7)</td>
<td>3.0 (0.7)</td>
<td>0.37</td>
</tr>
<tr>
<td>Systolic blood pressure (mmHg)</td>
<td>127 (13)</td>
<td>129 (16)</td>
<td>0.67</td>
</tr>
<tr>
<td>Diastolic blood pressure (mmHg)</td>
<td>74 (9.1)</td>
<td>71 (8.0)</td>
<td>0.16</td>
</tr>
<tr>
<td>Medication</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ACE-inhibitor/ARB</td>
<td>16 (62%)</td>
<td>21 (72%)</td>
<td>0.39</td>
</tr>
<tr>
<td>Acetylsalicylic Acid</td>
<td>22 (88%)</td>
<td>26 (90%)</td>
<td>1.00</td>
</tr>
<tr>
<td>Beta blocker</td>
<td>13 (50%)</td>
<td>15 (52%)</td>
<td>1.00</td>
</tr>
<tr>
<td>Calcium antagonist</td>
<td>6 (23%)</td>
<td>11 (33%)</td>
<td>0.23</td>
</tr>
<tr>
<td>Statin</td>
<td>25 (96%)</td>
<td>28 (97%)</td>
<td>1.00</td>
</tr>
<tr>
<td>Other cholesterol lowering drug</td>
<td>5 (19%)</td>
<td>2 (7%)</td>
<td>0.24</td>
</tr>
</tbody>
</table>

Categorical data: number (percentage). Continuous data: mean (SD) or median (Q1,Q3). AIT: Aerobic interval training, LED: Low energy diet, HDL: High density lipoprotein, ACE: Angiotensin converting enzyme, ARB: Angiotensin receptor blocker.
the small, dense LDLs. No such decrease in subfraction distribution was seen following the AIT (Fig. 2A, appendix A.3). Total HDL decreased similarly in both groups (Table 2). With the exception of HDL2b, all HDL subgroups decreased significantly following LED whereas this was only the case for HDL3a after AIT. For HDL3c, the between-group difference reached statistical significance. Again, a shift towards larger, less atherogenic HDL subfractions was seen after LED but not AIT (Fig. 2B, appendix A.3). The contribution of HDL to total lipoprotein at baseline was 56.2% (SD 9.5%) and 55.7% (SD 5.5%) in the AIT and LED group, respectively. This contribution increased by 2.2% (2.1%, 6.6%, P = 0.300) and 2.8% (0.7%, 4.8, P = 0.010) following AIT and LED, respectively, reflecting an increase in the proportion of total lipoprotein constituted by HDL despite the absolute decrease in total HDL.

The reduced atherogenicity following LED is also reflected by increased average particle size of LDL (baseline: 238 Å (SD 1.7)), within-group difference: 1.0 Å (95% CI 0.5; 1.4), P = 0.004) and HDL (baseline 90 Å (SD 1.6 Å), within-group difference: 0.9 Å (95% CI 0.3; 1.5), P = 0.004). No change was seen following AIT for neither LDL (baseline: 238 Å (SD 2.4), within-group difference: -0.1 Å (95% CI -0.6; 0.05), P = 0.831) nor HDL (baseline 91 Å (SD 2.5) within-group difference -0.4 Å (95% CI -1.4; 0.6), P = 0.448). LED was superior to AIT in increasing particle size (LDL: between-group difference: 1.0 Å (0.4; 1.7), P = 0.003, HDL: between-group difference: 1.2 Å (0.2; 2.4), P = 0.026). Nonetheless, all participants had the atherogenic LDL pattern B (LDL particle size <255 Å) characterized by a preponderance of small, dense LDL particles [24] both before and after intervention.

### 3.3. Inflammatory markers

No significant changes were seen in suPAR and CRP following the interventions. A statistically significant 9.5% decrease was seen in TNFα after LED while it remained unchanged following AIT. No between-group difference was seen on any of the inflammatory markers (Table 3). Intention-to-treat analyses comprising more participants revealed a statistically significant decrease in suPAR following LED but still no between-group difference (appendix A.1).

IL6 was dichotomized at the lower detection level of 2 ng/mL. Twenty-five (46%) and 29 (54%) participants had an IL6 < 2 pg/mL before and after the intervention, respectively. No between-group (P = 0.816) or within-group (LED: P = 0.688, AIT: P = 0.727) differences were seen.

#### 3.4. Adipose tissue, inflammatory markers and particle size

Linear regression including the entire population showed an association between increased HDL particle size and decreased visceral fat (β = -122, R² = 0.37, P < 0.001) and total fat mass (β = -7.5, R² = 0.13, P = 0.004). The association with subcutaneous fat was borderline significant (β = -58, R² = 0.10, P = 0.066). When adding the intervention to the model an independent effect was seen. Univariate regression divided by study group revealed a significant effect of LED but not AIT. The latter is possibly due to a smaller range in the difference of particle size and visceral fat. No associations were seen between LDL particle size and visceral fat (β = -42, R² = 0.02, P = 0.467) or subcutaneous fat (β = -84, R² = 0.09, P = 0.095) nor when regression was performed by group. Change in total fat mass and LDL particle size were associated (β = -7.8, R² = 0.06, P = 0.045). Linear regression showed no association between reduced triglyceride-levels and increased HDL (β = -0.02, R² = 0.01, P = 0.505) or LDL (β = 0.01, R² = 0.003, P = 0.688) particle size.

Reduced visceral fat was associated with decreased logCRP (β = 0.004, R² = 0.21, P = 0.008) whereas no association was seen between decreased logCRP and total body fat (β = 0.02, R² = 0.07, P = 0.065) or subcutaneous fat (β = 0.002, R² = 0.05, P = 0.215); suggesting a selective effect of visceral fat on logCRP. No association was seen between reduced adipose tissue and decreased logTNFα (visceral fat: β = -2.4, R² < 0.001, P = 0.976, subcutaneous fat: β = 1.3, R² = 0.001, P = 0.880, total fat mass: β = 3.4, R² = 0.006, P = 0.543) or logsuPAR (visceral fat: β = -39, R² = 0.005, P = 0.693, subcutaneous fat: β = -57, R² = 0.01, P = 0.514, total fat mass: β = 2.8, R² = 0.003, P = 0.673).
4. Discussion

The current paper demonstrates that both a rapid weight loss using an LED and 12-weeks’ of AIT decrease total lipoprotein, TRL and LDL whereas LED was superior to AIT in improving lipoprotein atherogenicity reflected by increased LDL and HDL particle size and

---

**Table 3**

<table>
<thead>
<tr>
<th></th>
<th>AIT (n = 25)</th>
<th>LED (n = 29)</th>
<th>Between group</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Baseline</td>
<td>Change (%)</td>
<td>P</td>
</tr>
<tr>
<td>CRP (mg/L)</td>
<td>1.86 (2.72)</td>
<td>–8.9 (–35.9; 29.5)</td>
<td>0.590</td>
</tr>
<tr>
<td>TNFα (pg/mL)</td>
<td>5.98 (1.34)</td>
<td>–3.7 (–13.6; 7.38)</td>
<td>0.486</td>
</tr>
<tr>
<td>suPAR (ng/mL)</td>
<td>4.49 (1.23)</td>
<td>–1.62 (–9.38; 6.81)</td>
<td>0.686</td>
</tr>
</tbody>
</table>

Baseline values: Mean (SD). Within-group change: Percentage change (95% C.I.). P-value: Within- and between-group differences. AIT: Aerobic interval training, LED: Low energy diet, CRP: C-reactive protein, TNFα: Tumor necrosis factor α, suPAR: Soluble urokinase plasminogen activator receptor.
a decrease in the proportion of LDL constituted by the small, dense LDL₅-subfraction. Moreover, TNFα was decreased following LED. It is the first study to compare the effects of weight loss obtained by an LED to those of an AIT program on lipoprotein atherogenicity and central markers of low-grade inflammation in a high-risk population with CAD and dyslipidemia. AIT was superior to LED in increasing VO₂peak while both interventions facilitated significant changes in body weight and composition; albeit, largest after LED as previously published [17].

4.1. Density profile

We have demonstrated a decrease in total cholesterol, nonHDL-cholesterol, total cholesterol/HDL-cholesterol-ratio and triglycerides following both interventions with no between-group difference [17]. These are all easily accessible measures of dyslipidemia and predictors of cardiovascular risk used in clinical practice [25,26]. Nevertheless, these LDL and HDL cholesterol assessments may have very different distributions of the small dense atherogenic lipoproteins with triglyceride-rich, cholesterol-depleted cores [1,4,5]. LDL cholesterol used in clinical practice is often calculated using Friedewald’s formula [3,4] and the accuracy of this estimate in subjects with the metabolic syndrome is still debated [27,28]. Thus, in clinical research lipoprotein density and size provide important additional information.

Most previous studies have used particle size to evaluate the effect of various interventions on lipoprotein atherogenicity. In the present study the LED group exhibited a shift toward a less atherogenic lipoprotein profile based on both particle size and density profile; the latter reflected by a relative improvement following LED compared to AIT in the atherogenic LDL₀, HDL₁₀ and HDL₀₂₀-subfractions. A randomized trial comparing 5% weight loss by moderate intensity exercise or caloric restriction showed that weight loss by caloric restriction caused a shift toward larger LDL-particles while LDL particle size remained unchanged after exercise-induced weight loss [29]. Thus, the effect of weight loss may depend on the weight loss mechanism. In overweight men a 10 kg weight loss increased LDL particle size without increasing HDL cholesterol in participants with LDL pattern B but not with LDL pattern A (average LDL size >255 Å) [24] suggesting that the effects of weight loss depends on a low baseline LDL particle size. With respect to HDL, a study comparing weight loss induced by diet or exercise found increased total HDL, HDL₂ and HDL₃ in both groups but no change in LDL cholesterol concentration in either group; however, LDL subfractions were not measured [30].

While two of the studies cited above compared weight loss obtained by diet or exercise, few studies have examined the effect of exercise without weight loss. In agreement with our observations, exercise inducing a small weight loss in a healthy overweight population caused no significant change in LDL or HDL particle size [31]. The STRRIDE study demonstrated that a high amount of high-intensity exercise is required to change the lipoprotein density and particle size [32]. The importance of training intensity could explain the unaltered particle size following the 5% exercise-induced weight loss in the trial cited above [29]. The participants in the STRRIDE study underwent 8 months’ exercise at an intensity comparable to ours but with a higher weekly frequency of exercise sessions accentuating training duration. In our study 12 weeks’ AIT three times/week may be sufficient to decrease the amount of lipoprotein but insufficient to affect atherogenicity.

In the STRRIDE study the group undergoing high-amount, high-intensity exercise obtained the greatest decrease in body weight, fat mass and abdominal obesity [33]. In the present study, LED was superior to AIT in decreasing body weight, body fat mass, subcutaneous and visceral abdominal fat [17]. Lipoprotein particle size has been linked to abundance of adipose tissue and, in particular, visceral fat [2,19] and changes in atherogenicity could be related to changes in body composition. The association between increased HDL particle size and decreased total and visceral fat mass lends support to this pathogenic mechanism. The results were less clear regarding LDL particle size, which was only associated with reduced total fat mass. This association did not persist when separating the groups.

Since increased triglyceride-levels promote the formation of small lipoprotein particles [5] the decrease in triglycerides observed previously [17] corresponds well to the shift toward larger, less dense lipoproteins. Triglycerides have been shown to predict LDL particle size in physically active and sedentary men [34]. Thus, it was unexpected that no link was seen between increased LDL and HDL particle size and decreased triglyceride-levels. Alternatively, a decrease in the enzyme hepatic lipase, which is not measured in the present study, has been connected to decreased visceral fat [19]. This enzyme catalyzes the hydrolysis of core triglycerides resulting in smaller, denser lipoproteins [35].

4.2. Inflammatory markers

Existing evidence concerning the effects of exercise on low-grade inflammation is equivocal. In the current study AIT did not lead to statistically significant changes in IL6, TNFα or CRP. A study comprising 12 participants with heart failure due to CAD undergoing 4 months’ combined endurance and resistance training obtained no change in IL6 and TNFα; nonetheless, a significant decrease in soluble TNF1 and TNF2-receptors suggested an attenuated inflammatory response [36]. CAD patients enrolled in a cardiac rehabilitation program including 12 weeks’ aerobic exercise achieved a significant decrease in CRP [37,38] and IL6 [38] independently of weight change and statin treatment. However, in both studies baseline CRP-levels were considerably higher than in the present population. In 96 CAD patients with CRP-levels more similar to ours an eight-week exercise-based cardiac rehabilitation program did not affect CRP, IL6 and TNFα levels despite improved VO₂peak [39]. To further support our findings, six months’ aerobic exercise training in an at-risk population did not decrease CRP despite improved fitness and body composition [40]. The acute increase in inflammatory markers subsequent to exercise [41,42] could mask a more long-term decrease in inflammatory markers. However, CRP and IL6 are both normalized 20 h after exercise [41,42]. In the current study blood samples were taken >18 h after the last exercise session.

A review comprising 33 interventional studies conclude that CRP decreases following weight loss [43]. Our LED group achieved a significant decrease in TNFα suggesting decreased low-grade inflammation. This was accompanied by a 26.3% decrease in CRP but statistical significance was not reached. Intention-to-treat analyses including more participants showed a borderline significant 27.5% decrease in CRP (P = 0.059, appendix A.1) indicating that the small sample size could explain the lack of statistical significance in per protocol analyses. High intra-assay variability of the high-sensitivity CRP assay and high within-individual variability of CRP [44] presuppose a large sample size to detect an effect of the intervention.; in particular, when baseline CRP concentrations are modest as in the present study. Mean CRP was only slightly higher than a healthy population [45] and considerably lower than in overweight CAD patients participating in cardiac rehabilitation [37,38]. This was also reflected by the IL6-measurement with IL6 below the lower detection-limit in 46% of the participants. Thus, the limited effect on low-grade inflammation could relate to the low baseline values.

As opposed to the other inflammatory markers presented there
is a paucity of evidence regarding the effect of weight loss and exercise on suPAR. A cross-sectional study has shown that suPAR is positively associated with self-reported physical activity while there is a negative association with BMI and waist circumference; however, this association was only seen in smokers [46]. In 12 professional football players no acute effect on suPAR levels was seen after a match [47]. This is the first study to examine the effects of an AIT and weight loss program on suPAR levels revealing a modest decrease following LED, though only statistically significant in the intention-to-treat analyses.

Low-grade inflammation is linked to visceral adipose tissue [2,18] and changes in low-grade inflammation could be related to changes in body composition. TNFα was reduced after LED and it was somewhat unexpected that no association was seen between decreased TNFα and decreased measures of body fat while decreased CRP was correlated to decreased visceral fat. However, the same applies in a cross-sectional analyses based on the Framingham study demonstrating that visceral fat is related to the level of CRP but not TNFα [18].

4.3. Limitations

When transferring the results to the general population of CAD patients generalizability must be considered. Our participants enrolled voluntarily and could be more inclined to change their lifestyle than CAD patients in general. Engaging in intensive lifestyle changes requires a certain mental and physical discipline from the participants and support from family and employers. This is supported by the observation reported previously [17] that a large proportion (87%) of the participants had >10 years education and was cohabitant (71%). A larger proportion of those who did not complete the intervention were employed compared to those who did. Based on the exclusion criteria a direct translation of the results to CAD patient with co-morbidities such as diabetes, severe heart failure or COPD should be done with caution.

Regarding study design the sample size calculation was based mainly on the trial’s primary end point: coronary flow reserve [23]. The relatively small sample size could partly explain the limited effect on low-grade inflammation as discussed above. Since the aim of the study was to compare two intervention modalities the design did not include a control group. A control group, although not blind to the intervention, could elucidate any placebo effect. However, participants were all motivated for lifestyle changes and requiring them to refrain from changing their lifestyle for the entire duration of the trial, 12 months, was thought to be problematic since it is not in line with current guidelines [3].

5. Conclusion

The present study demonstrates that both LED and AIT decrease total and LDL lipoprotein whereas LED is superior to AIT in decreasing lipoprotein atherogenicity. This may be explained by a larger decrease in total fat mass and visceral abdominal fat following LED. Neither intervention had marked effects on inflammatory markers although a significant decrease in TNFα was seen following LED. The present study concerns the short-term effect of weight loss and exercise; however, in secondary prevention sustainability is pivotal. The study design comprises a 40-week maintenance period and a one-year follow-up. Future analyses will reveal whether the effects on inflammation and atherogenic markers are sustainable.

Sources of funding

The work was supported by The Danish Council for Independent Research; The Faculty of Health and Medical Sciences, University of Copenhagen; The Danish Heart Foundation; Bispebjerg Hospital; Beckett Foundation; Else and Mogens Wedell-Wedelborg’s Foundation. The Cambridge Weight Plan supplied the LED. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.

Clinicaltrials.gov

NCT01724567.

Disclosures

JEO is a founder, shareholder and board member of ViroGates A/S, Denmark, the company that produces the suPARnostic® assay. JEO and SBH are inventors on a patent on suPAR and risk. Hvidovre Hospital, University of Copenhagen, Denmark, owns the patent, which is licensed to ViroGates A/S.

Acknowledgments

We thank Adam Kieffer for technical assistance in performing the lipoprotein density profiling.

Appendix A. Supplementary data

Supplementary data related to this article can be found at http://dx.doi.org/10.1016/j.atherosclerosis.2016.01.001.

References


